Adam Koppel Ph.D Overview

  • Primary Position
  • Partner, Life Sc...

  • Primary Industry
  • Healthcare

  • Active Board Seats
  • 5

  • Med. Deal Size

  • Med. Valuation

Adam Koppel Ph.D General Information

Biography

Dr. Adam Koppel serves as Partner, Life Science at Bain Capital. Dr. Koppel serves as Partner in life Sciences at Bain Capital Life Sciences. He is an Angel Investor. He served as a Board Member at Cerevel Therapeutics. He also serves as a Board Member at Foghorn Therapeutics, Cardurion Pharma, and Cerevel Therapeutics. He served as a Board Member at Solid Biosciences and ViaCyte. He serves as an Advisor at Binney Street Capital. He initially joined Bain Capital Public Equity in 2003 where he was a leader within the healthcare sector until mid-2014. During the period from mid-2014 to mid-2016, he was at Biogen where he served as EVP of Corporate Development and Chief Strategy Officer. Before initially joining Bain Capital in 2003, he was an Associate Principal at McKinsey & Co. in New Jersey where he served a variety of healthcare companies. He also serves as an Advisory Board Member at Partners HealthCare Innovation. Prior, he served as Managing Director at Bain Capital Public Equity. He has served as Chief Strategy Officer and Executive Vice President at Biogen. He has also served as a board member at PTC Therapeutics.

Contact Information

Primary Position
Partner, Life Science, Bain Capital
Education
University of Pennsylvania (Wharton), MBA (Master of Business Administration)
University of Pennsylvania, Ph.D. (Doctor of Philosophy)
University of Pennsylvania, MD (Doctor of Medicine)
Harvard University, MA (Master of Arts)
Harvard University, BA (Bachelor of Arts)
Harvard University, Graduate
Gender
Male
Total Investments
Email
ak
Phone
+1 (617)
Address
  • 200 Clarendon Street
  • Boston, MA 02116
  • United States
+1 (617)

Adam Koppel Ph.D Positions (2)

Firm name Firm type Title Location Industry Since
Bain Capital Investor Partner, Life Science Boston, MA PE/Buyout
Bain Capital Life Sciences Investor Partner, Life Sciences Boston, MA Corporate Venture Capital

Adam Koppel Ph.D Board Seats (5)

Company Industry Ownership Status Financing Status Location Since
Aptinyx Drug Discovery Privately Held (backing) Formerly VC-backed Evanston, IL
Areteia Therapeutics Drug Discovery Privately Held (backing) Venture Capital-Backed Chapel Hill, NC
Cardurion Biotechnology Privately Held (backing) Venture Capital-Backed Burlington, MA
Foghorn Therapeutics Biotechnology Publicly Held Formerly VC-backed Cambridge, MA
Mass General Brigham Innovation Cambridge, MA

Adam Koppel Ph.D Lead Partner on Deals (11)

Adam Koppel Ph.D has been the lead partner on 11 deals. Their latest deal was with Cardurion, a biotechnology company. The deal was made for on 10-Jul-2024.

Company Deal Date Deal Type Deal Size Deal Status Industry Location
Cardurion 10-Jul-2024 Later Stage VC (Series B) Completed Biotechnology Burlington, MA
Areteia Therapeutics 12-Feb-2024 Completed Drug Discovery Chapel Hill, NC
Solid Biosciences 08-Jan-2024 Completed Biotechnology Charlestown, MA
Cardurion 12-Jul-2023 Completed Biotechnology Burlington, MA
Solid Biosciences 05-Dec-2022 Completed Biotechnology Charlestown, MA
Synapticure 01-Feb-2022 Completed Clinics/Outpatient Services Chicago, IL
ViaCyte 09-Jun-2021 Completed Drug Discovery San Diego, CA
Solid Biosciences 15-Dec-2020 Completed Biotechnology Charlestown, MA
Cerevel Therapeutics 27-Oct-2020 PIPE Completed Drug Discovery Cambridge, MA
ViaCyte 26-May-2020 Later Stage VC (Series D2) Completed Drug Discovery San Diego, CA

Adam Koppel Ph.D Network (215)

Board Members (111)

Name Company Representing Location From
Glenn Steele Ph.D PTC Therapeutics Self Warren, NJ
Allan Jacobson Ph.D PTC Therapeutics Self Warren, NJ
Areteia Therapeutics Areteia Therapeutics Chapel Hill, NC
Mass General Brigham Innovation Self Cambridge, MA
Cardurion Self Burlington, MA

Portfolio Executives (97)

Name Company Role Deal date Location
Rebecca Frey Cardurion Chief Operating Officer & Advisor 10-Jul-2024 Burlington, MA
Emma Reeve Cardurion Board Member & Audit Chair 10-Jul-2024 Burlington, MA
Cardurion Chief Operating Officer 10-Jul-2024 Burlington, MA
Cardurion Chief Financial Officer 10-Jul-2024 Burlington, MA
Cardurion Chief Medical and Scientific Officer & Head of Translational Medicine 10-Jul-2024 Burlington, MA

Fund Team Members (7)

Name Investor Fund Fund Location
Jeffrey Schwartz Bain Capital Bain Capital Life Sciences Fund IV Boston, MA
Jeffrey Schwartz Bain Capital Life Sciences Bain Capital Life Sciences Fund IV Boston, MA
Bain Capital Boston, MA
Bain Capital Life Sciences Boston, MA
Bain Capital Boston, MA

Adam Koppel Ph.D Affiliated Funds (1)

Fund Investor Fund Type Status Vintage Size Dry Powder IRR IRR Quartile
Bain Capital Life Sciences Fund IV Bain Capital Growth/Expansion Closed 2024

Adam Koppel Ph.D Advisory Roles (1)

Firm name Firm type Title Location Industry Since
Binney Street Capital Investor Advisor Boston, MA Corporate Venture Capital

Adam Koppel Ph.D FAQs

  • Who is Adam Koppel Ph.D?

    Dr. Adam Koppel serves as Partner, Life Science at Bain Capital.

  • How much does Adam Koppel Ph.D typically invest?

    Adam Koppel Ph.D's median deal size is .

  • What is Adam Koppel Ph.D’s main position?

    Adam Koppel Ph.D’s primary position is Partner, Life Science.

  • What are the contact details for Adam Koppel Ph.D?

    Adam Koppel Ph.D’s email address is ak and his phone number is +1 (617) .

  • How many active board seats does Adam Koppel Ph.D hold?

    Adam Koppel Ph.D holds 5 board seats including Aptinyx, Areteia Therapeutics, Cardurion, Foghorn Therapeutics, and Mass General Brigham Innovation.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »